Genetic Diseases Could See Indication Expansions Through Accelerated Approval
Accelerated approvals likely to increase, particularly for cancer, predicts FDA’s Temple.
You may also be interested in...
CDER’s Bob Temple explains how competitors could actually help speed up a drug approval but also hold a product to a higher standard.
Five-point plan that calls for FDA to change definition of ‘labeling’ and ‘substantial evidence’ may offer hints as to what the next iteration of 21st Century Cures legislation will offer.
Breast cancer meeting highlights challenges of patient-focused drug development as breast cancer patients ask for trials to better identify characteristics of super-responders so patients can make more informed risk-benefit decisions.